Loading…
← CockpitCompetitor Analysis › MSB.AX Mesoblast LimitedOpen in the cockpit ↗

Mesoblast LimitedMSB.AXCompetitor analysis, valuation and peers

Australia · AUD·Health Care›Biotechnology

Develops cell therapies from mesenchymal stem cells, including an approved treatment for graft-versus-host disease.

≈ A small-cap cell-therapy biotech, like a mini Bluebird BioMomentum weak 25
Mkt cap
$1.49B
US dollars, full cap
Free float
65%
of shares outstanding
$/day
$4.49M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-19.2 pp
WACC 13.0%
Hurdle
n/a
no reverse DCF
Next earnings
106 days
4 Mar 2027
Close · AUDA$1.76
1D-1.9%
1W-13.3%
1M0.0%
3M-25.4%
6M-17.0%
YTD-35.3%
1Y-23.5%
ATR %6.1%
52w lowhigh46.8% off high

What Mesoblast does

Develops cell therapies from mesenchymal stem cells, including an approved treatment for graft-versus-host disease.

Until Ryoncil's approval in late 2024 it lived on investor funding and licensing fees; since the 2025 US launch it earns product sales through transplant centers treating children, while its heart-failure and back-pain programmes are paid for from capital raised. The company is Melbourne-based, with an ADR listing in the US.

In one line: A small-cap cell-therapy biotech, like a mini Bluebird Bio.

Products and services

  • Ryoncil (graft-versus-host disease)
  • Heart failure cell therapy pipeline
  • Chronic pain therapy pipeline

Customers

  • Hospitals/transplant centers
  • Pharma licensing partners

Where it sits in the supply chain

  • Stem cell therapy R&D
  • Manufacturing (cell therapy)
  • Sale to hospitals/transplant centers

What could go right

  • Ryoncil commercial ramp-up
  • New indication approvals

What could go wrong

  • Clinical trial failure risk
  • Cash burn/dilution risk

Moat: narrow (IP / patents). Patented mesenchymal stem cell platform and a rare FDA-approved cell therapy product.

Headquarters: Melbourne, Australia · Founded: 2004 · Employees: 108

Named competitors

Mesoblast at a glance

Size Mesoblast (MSB.AX) is an Australia Health Care company (Biotechnology) with a market value of $1.49B, the 138th largest of 317 Australia companies the cockpit tracks. Shares closed at A$1.76 on 18 Nov 2026.

Performance Over six months the shares fell 17.0%, against -6.9% for the median peer and +1.2% for the Australia market (cap-weighted) — 9th lowest of 20 in its peer set.

Growth Revenue grew 555.7% over the last twelve months (peer median +24.8%); the operating margin is -43.2% (peer median -9.6%).

Valuation It trades at 12.8× enterprise value to sales against a peer median of 10.1× (9th most expensive of 18).

Capital Return on invested capital runs 19.2 points below its cost of capital (13.0% WACC).

Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 92MSB.AX 85
Six months, rebased to 100: Mesoblast against the median of its 20 peers (local-currency closes).

Mesoblast financials

Reported figures in AUD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueA$176MA$177MA$26.6MA$9.01MA$11.2M
Revenue growth—+568%+195%-19%—
Gross profitA$148MA$149MA$8.75M-A$15.0M-A$30.1M
EBITDA-A$63.5M-A$63.0M-A$86.7M-A$82.6M-A$102M
Net income-A$86.0M-A$84.9M-A$158M-A$134M-A$122M
Free cash flow-A$96.5M-A$100M-A$88.4M-A$85.5M-A$103M
Capital expenditureA$1.28MA$1.33MA$1.13MA$505,054A$466,773
Total debtn/aA$184MA$196MA$178MA$175M

Quarterly statements and history in the cockpit →

Mesoblast competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-50%0%+50%0870102637688319URGNKRSA688765KLRAPGENIMCRNRIX688105ABSIANABRAPP688185PPGN4588MSB.AX6-month return →1-month return →
Up and to the right = strong over both horizons. Mesoblast is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%0×500×1,000×087010688319URGNKRSA688765PGENNRIXQUREABSIVIR4588MSB.AXRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Mesoblast is the large dot.

Mesoblast competitors and peer comparison

Head to head with its named competitors (MSB.AX vs VCEL)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Mesoblast MSB.AX$1.49B-17%+556%-43%12.8×n/a
Vericel VCEL$2.99B+66%+25%8%9.0×46.5%

How Mesoblast compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Mesoblast against its 20 peers (data as of 18 Nov 2026)
MeasureMSB.AXPeer medianRank in peer set
1-month return0.0%-12.7%4th highest of 21
6-month return-17.0%-6.9%9th lowest of 20
Distance from 52-week high-46.8%-44.1%9th lowest of 21
Revenue growth (TTM)+555.7%+24.8%5th highest of 18
Operating margin-43.2%-9.6%9th lowest of 19
EV / Sales12.8×10.1×9th most expensive of 18
ROIC minus cost of capital-19.2 pp-9.5 pp5th lowest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Mesoblast MSB.AXAustralia$1.49B-17%+556%-43%12.8×n/an/a
Peptron 087010.KSSouth Korea$1.49B-68%-13%-488%359.6×n/an/a
TLC BioSciences 7924.TWOTaiwan$1.50Bn/an/an/an/an/an/a
Fujian Haixi Pharmaceuticals 2637.HKHong Kong$1.47B-32%+25%33%n/an/an/a
Chengdu Olymvax Biopharmaceuticals 688319.SSChina$1.51B-37%+12%8%13.1×n/an/a
UroGen Pharma URGNUnited States$1.46B-1%+159%-12%6.3×n/an/a
Korsana Biosciences KRSAUnited States$1.52B+54%-64%-5,277%1,058.7×n/an/a
Wuhan Healthgen Biotechnology 688765.SSChina$1.46B-51%+90%-297%205.0×n/an/a
Kailera Therapeutics KLRAUnited States$1.53B-41%n/an/an/an/an/a
Precigen PGENUnited States$1.53B0%+2,388%21%10.1×n/an/a
Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCRUnited States$1.44B-7%+13%-7%2.3×n/an/a
Nurix Therapeutics NRIXUnited States$1.54B-14%+739%41%0.8×n/an/a
Nanjing Vazyme Biotech 688105.SSChina$1.42B+25%+16%-5%4.9×39.4%-2.5%
uniQure QUREUnited States$1.42B-17%+28%-1,027%65.4×n/an/a
Absci ABSIUnited States$1.41B+65%-47%-9,155%835.7×n/an/a
Vir Biotechnology VIRUnited States$1.57B+3%+1,696%-70%4.0×n/an/a
AnaptysBio ANABUnited States$1.40B-22%+13%62%7.9×0.5%+25.6%
Rapport Therapeutics RAPPUnited States$1.39B-34%n/a-838%50.1×n/an/a
CanSino Biologics 688185.SSChina$1.38B0%+30%-4%6.6×n/an/a
PolyPeptide PPGN.SWSwitzerland$1.61B+7%+22%7%3.4×n/an/a
Oncolys BioPharma 4588.TJapan$1.37B+181%+1,749%-295%408.9×n/an/a

Questions

Who are Mesoblast's main competitors?
Named competitors: Bluebird Bio (private or unlisted), Vericel Corporation (VCEL), Athersys (private or unlisted). The cockpit's measured peer set (industry) also includes Peptron (087010.KS), TLC BioSciences (7924.TWO), Fujian Haixi Pharmaceuticals (2637.HK), Chengdu Olymvax Biopharmaceuticals (688319.SS), UroGen Pharma (URGN), Korsana Biosciences (KRSA).
Is Mesoblast expensive compared with its peers?
On ev / sales it trades at 12.8× against a peer median of 10.1×, 9th most expensive of 18 in its peer set.
How has Mesoblast stock performed?
Over six months to 18 Nov 2026 the shares returned -17.0% against -6.9% for the median peer; over one year -23.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.